Document is current
Any future updates will be listed below
-
Authors
Armstrong, April W. https://orcid.org/0000-0003-0064-8707
Warren, Richard B. https://orcid.org/0000-0002-2918-6481
Sofen, Howard https://orcid.org/0000-0001-7789-6915
Spelman, Lynda https://orcid.org/0000-0002-7330-4713
Linaberry, Misti
Becker, Brandon
Jou, Ying-Ming
Daamen, Carolin
Kimball, Alexa B.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03624127 at ClinicalTrials.govnct03611751 at ClinicalTrials.govDocuments that mention this clinical trial
AB1098 DEUCRAVACITINIB IN PLAQUE PSORIASIS: 2-YEAR LABORATORY RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM
https://doi.org/10.1136/annrheumdis-2023-eular.1533
AB1086 COVID-19–RELATED ADVERSE EVENTS IN THE PHASE 3 POETYK TRIALS OF THE ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, DEUCRAVACITINIB, IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
https://doi.org/10.1136/annrheumdis-2023-eular.1709
POS1042 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY
https://doi.org/10.1136/annrheumdis-2021-eular.1002
Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK Analysis
https://doi.org/10.1007/s13555-025-01606-9
FRI0435 INFLUENCE OF BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS ON EFFICACY OF AN ORAL, SELECTIVE TYK2 INHIBITOR, BMS-986165, IN PATIENTS WITH PLAQUE PSORIASIS IN A PHASE 2 TRIAL
https://doi.org/10.1136/annrheumdis-2019-eular.1762
AB1374 DEUCRAVACITINIB IN PLAQUE PSORIASIS: MAINTENANCE OF RESPONSE OVER 3 YEARS
https://doi.org/10.1136/annrheumdis-2024-eular.245
AB0890 Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials
https://doi.org/10.1136/annrheumdis-2022-eular.1377
Documents that mention this clinical trial
AB1098 DEUCRAVACITINIB IN PLAQUE PSORIASIS: 2-YEAR LABORATORY RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM
https://doi.org/10.1136/annrheumdis-2023-eular.1533
AB1086 COVID-19–RELATED ADVERSE EVENTS IN THE PHASE 3 POETYK TRIALS OF THE ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, DEUCRAVACITINIB, IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
https://doi.org/10.1136/annrheumdis-2023-eular.1709
Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK Analysis
https://doi.org/10.1007/s13555-025-01606-9
FRI0435 INFLUENCE OF BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS ON EFFICACY OF AN ORAL, SELECTIVE TYK2 INHIBITOR, BMS-986165, IN PATIENTS WITH PLAQUE PSORIASIS IN A PHASE 2 TRIAL
https://doi.org/10.1136/annrheumdis-2019-eular.1762
AB1374 DEUCRAVACITINIB IN PLAQUE PSORIASIS: MAINTENANCE OF RESPONSE OVER 3 YEARS
https://doi.org/10.1136/annrheumdis-2024-eular.245
AB0890 Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials
https://doi.org/10.1136/annrheumdis-2022-eular.1377
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb (NIHR203308)
- License Information
-
More Information
Article History
Received: 16 October 2025
Accepted: 13 November 2025
First Online: 5 December 2025
Declarations
:
: April W. Armstrong has served as a research investigator, scientific advisor, and/or speaker for AbbVie, Almirall, Arcutis, Aslan, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, EPI Health, Incyte, Janssen, LEO Pharma, Lilly, Mindera Health, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB. Richard B. Warren is an Editor-in-Chief of Dermatology and Therapy and was not involved in the selection of peer reviewers for this manuscript nor any of the subsequent editorial decisions. Professor Warren has received research grants from AbbVie, Almirall, Amgen, Celgene, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, and UCB and consulting fees from AbbVie, Almirall, Amgen, Astellas, Boehringer Ingelheim, Celgene, DICE Therapeutics, GSK, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi, UCB, and Union Therapeutics. Howard Sofen has served as a clinical investigator for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, LEO Pharma, Lilly, Novartis, and Sun Pharma. Lynda Spelman has served as a consultant, paid investigator, clinical advisory board member and/or speaker for AbbVie, Amgen, Anacor, AnaptysBio, Ascend, Astellas, AstraZeneca, Blaze Bioscience, Boehringer Ingelheim, Botanix, Bristol Myers Squibb, Celgene, ConnectBiopharma, Genesis Care, Dermira, Eli Lilly, Enkang Pharmaceuticals, Equillium, Evelo Biosciences, Genesis Care, Galderma, Genentech, GlaxoSmithKline, Hexima, Incyte, InflaRx GmbH, Invion, Janssen, Kiniksa Pharmaceuticals, Kobio Labs, LG Chem, Lipidio Pharma, LEO Pharma, Mayne, Medimmune, Merck, Merck-Serono, Novartis, Nektar Therapeutics, Olix Pharmaceuticals, Otsuka, Pfizer, Phosphagenics, Photon MD, Principia, Regeneron, Ribon, Samumed, Sanofi Genzyme, SHR, Sun Pharma, Takeda, UCB, and Zai Lab. Misti Linaberry, Brandon Becker, and Ying-Ming Jou are employees of and shareholders in Bristol Myers Squibb. Carolin Daamen was an employee of and shareholder in Bristol Myers Squibb at the time of study conduct. Alexa B. Kimball’s institution received grants from AbbVie, AnaptysBio, Bristol Myers Squibb, Eli Lilly, Incyte, Janssen, MoonLake Immunotherapeutics, Novartis, Pfizer, Prometheus, Sanofi, Sonoma Biotherapeutics, and UCB; she received consulting fees from AbbVie, Boehringer Ingelheim, Eli Lilly, Janssen, MoonLake Immunotherapeutics, Novartis, Takeda, Target RWE, UCB, Union Therapeutics, and Ventyx; and serves on the board of directors of Almirall.
: The POETYK PSO-1 and PSO-2 trials were conducted in accordance with Good Clinical Practice, as defined by the International Council for Harmonization and Declaration of Helsinki. Independent institutional review board approvals were obtained and all participants provided written informed consent.
